Neurocrine Q4 revenue rose to $627.7 million; GAAP net income fell to $103.1 million
Neurocrine Biosciences reported fourth-quarter 2024 total revenues of $627.7 million, up from $515.2 million a year earlier, driven by INGREZZA net product sales of $615 million. GAAP net income fell to $103.1 million, or $1.00 per diluted share, from $147.7 million, or $1.44, as operating expenses rose, while non-GAAP diluted EPS rose to $1.69 from $1.54. The company also issued full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.6 billion.
Key points
- Q4 2024 total revenues $627.7 million vs. $515.2 million in Q4 2023; full-year 2024 total revenues $2,355.3 million vs. $1,887.1 million
- Q4 2024 GAAP diluted EPS $1.00 vs. $1.44; non-GAAP diluted EPS $1.69 vs. $1.54, with the company citing $28 million of higher stock-based compensation tied to CRENESSITY approval and the CEO retirement charge
- CRENESSITY fourth-quarter 2024 net product sales were $2 million, reflecting initial pharmacy orders after FDA approval in December 2024
- Full-year 2025 guidance: INGREZZA net product sales of $2.5 billion to $2.6 billion; non-GAAP R&D of $890 million to $940 million and non-GAAP SG&A of $955 million to $975 million
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.